CalciMedica Collaborates with Telperian on AI-Driven Clinical Trial Analysis

• CalciMedica and Telperian collaborate on AI engine integration • AI tools to analyze Phase 2 datasets for patient populations and efficacy endpoints • Auxora, CalciMedica's lead compound, being developed for acute inflammatory and immunologic illnesses • Telperian's AI engine will refine target patient populations and efficacy endpoints for pivotal trials • Collaboration aims to optimize clinical trial strategies for Auxora and future CRAC channel inhibitors.

CalciMedica Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in novel calcium release-activated calcium (CRAC) channel inhibition therapies, has announced a strategic collaboration with Telperian, a clinical trial intelligence company. The partnership aims to integrate Telperian's artificial intelligence (AI) engine into the analysis of clinical trial datasets from completed trials of Auxora™, CalciMedica's lead compound.

Auxora, a potent and selective small molecule CRAC channel inhibitor, is being developed for use in patients with acute inflammatory and immunologic illnesses. The AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials. This collaboration is expected to provide deep, data-supported insights into the benefits of treatment with Auxora to different patient subtypes, as well as other discernible patterns and benefits of treatment.

Telperian's platform, powered by AI, biostatistics, and domain expertise, includes its asynchronous review platform for statistical data in regulatory submissions, its ability to leverage historical evidence for design intelligence, its novel subtyping methodologies, and its deep study design expertise. By applying these tools to the clinical trial data of Auxora, Telperian will provide CalciMedica with the insights needed to optimize clinical trial strategies for Auxora and future CRAC channel inhibitors.

Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica, commented, "CARPO and CARDEA are two critical trials contributing to the strong body of evidence supporting Auxora as a potentially transformative treatment for acute inflammatory and immunologic illnesses. This collaboration with Telperian will help us refine our target patient populations and efficacy endpoints, ultimately enhancing the clinical development of Auxora."

This collaboration is a significant step for CalciMedica, as it leverages advanced AI technologies to improve the efficiency and effectiveness of its clinical trials. The integration of Telperian's AI engine will not only streamline the analysis of clinical trial data but also provide valuable insights that could accelerate the regulatory approval process for Auxora.